Entries by Maren Kühr

After the setback, what's next for biotech stocks?

While the Nasdaq Biotechnology index saw a huge uplift during the pandemic (+ 77% since March 2020 until reaching a peak in August 2021), it lost 27% during the last six months vs a 11%/4% decline for the Nasdaq Composite and the S&P 500, respectively

Automated workflow

The SARS-CoV-2 virus global outbreak generated a need for fast and reliable large-scale testing. One of the main bottlenecks of the PCR test is the laborious and time-consuming molecular method for viral genetic material extraction. BioEcho Life Sciences, together with Hamilton and the German diagnostics laboratory ‘Labor Dr. Fenner und Kollegen’ developed an automated workflow for 96- and 48-well plate formats.

Lasers to personalise therapy

Biotechnology is a key market segment for Coherent. We provide innovative solutions for academic research, pharma discovery, translational research, clinical testing, and interventional therapeutics. We support these applications with lasers, laser engines, fibers, and fiber optic components.

Austria magnet for biotechnology

The life sciences location of Austria has gained considerable momentum since the ­founding of the very first Austrian biotech company Intercell at the turn of the millennium. Today the who’s who of the biotech sector relies on Austria, in particular on its capital city of Vienna.

The Next Big Thing: “Biologisation”

The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy

The Next Big Thing: "Biologisation"

The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy